Canada markets closed

Rakovina Therapeutics Inc. (RKV.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.0800-0.0050 (-5.88%)
At close: 09:47AM EDT
Full screen
Previous Close0.0850
Open0.0800
Bid0.0800 x N/A
Ask0.0850 x N/A
Day's Range0.0800 - 0.0800
52 Week Range0.0050 - 0.1400
Volume25,000
Avg. Volume78,548
Market Cap5.607M
Beta (5Y Monthly)0.23
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateMay 29, 2024 - Jun 03, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

    All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) announces that in accordance with the terms of an indenture entered into between the Company and Odyssey Trust Company dated May 29, 2023 (the “Indenture”), certain holders (each, a “Debentureholder”) of 12.0 per cent unsecured convertible debentures of the Company (the “Debentures”) have elected to receive common sha

  • GlobeNewswire

    Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement

    All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the undertaking of a non-brokered Private Placement (the “Offering”) for gross proceeds of up to $1.5 million at a purchase price of $0.10 per Unit. This includes l

  • GlobeNewswire

    Rakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research

    Expanded Activities Position Rakovina Therapeutics to Capitalize on AI Partnerships with The University of British Columbia and Pharma Inventor Inc.VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the expansion of two research collaborations to align with its re